Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05856695 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

Study acronym: TAXIO
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Feb 2026 → Nov 2026
See other at-risk trials from Intergroupe Francophone de Cancerologie Thoracique

Record History

  1. Primary completion pushed from Feb 2026 to Nov 2026 Completion pushed from Feb 2028 to Nov 2028v7 Show 1 more changeShow less
    • Completion pushed from Feb 2028 to Nov 2028
  2. Trial status: Recruiting to Active, Not Recruiting Site details revised at 31 of 31 sitesv6 Show 1 more changeShow less
    • Site details revised at 31 of 31 sites
  3. Study title shortened, about 11 wordsv5 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 27 to 31 Eligibility criteria expanded, about 474 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 474 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 28 to 27 · Primary completion date: Nov 2025 to Feb 2026 · Completion date: Dec 2027 to Feb 2028 · 1 morev3 Show 4 more changesShow less
    • Study sites: 28 to 27
    • Primary completion date: Nov 2025 to Feb 2026
    • Completion date: Dec 2027 to Feb 2028
    • Start date changed from estimate of Sep 2023 to Nov 17, 2023
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The current study is intended to be a "proof of concept" to evaluate the potential value of synergy between paclitaxel carboplatin and immunotherapy. If a signal clearly shows superiority over the CASPIAN data , we will have arguments to think that the combination of paclitaxel and carboplatin is more suitable for synergy with immunotherapy than the standard etoposide and carboplatin.
Trial Details
NCT Number NCT05856695
Lead Sponsor Intergroupe Francophone de Cancerologie Thoracique
Conditions Small Cell Lung Cancer Extensive Stage
Enrollment 67 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov